Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 1112-1114, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simpson, J. A.
Right arrow Articles by Van Eyk, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simpson, J. A.
Right arrow Articles by Van Eyk, J. E.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:1112-1114.)
© 2002 American Association for Clinical Chemistry, Inc.


Technical Briefs

Differential Detection of Skeletal Troponin I Isoforms in Serum of a Patient with Rhabdomyolysis: Markers of Muscle Injury?

Jeremy A. Simpson1,2,1, Ralf Labugger1,2,1, Geoffrey G. Hesketh1, Christine D’Arsigny3,5, Denis O’Donnell3,5, Nobuko Matsumoto6, Christine P. Collier2,5, Steve Iscoe1 and Jennifer E. Van Eyk1,4a

Departments of
1 Physiology,
2 Pathology,
3 Respirology, and
4 Biochemistry, Queen’s University, and
5 Kingston General Hospital, Kingston, Ontario, K7L 3N6 Canada;
6 Internal Medicine, Sagamihara Kyodo Hospital, Hashimoto 2-8-18, Sagamihara, Kanagawa 229, Japan

aauthor for correspondence: Queen’s University, Department of Physiology, Kingston, Ontario, K7L 3N6 Canada; fax 613-533-6880, e-mail jve1@post.queensu.ca

The first 20% of the full text of this article appears below.

Unlike the extensive research devoted to the development of troponin-based diagnostic assays for myocardial disease, much less effort has been expended on the development of a counterpart for skeletal muscle disorders. The consensus that the cardiac troponins [cardiac troponin I (cTnI) and/or cTnT] should be used for diagnosis of myocardial infarction (MI), as well as for diagnosis and management of unstable angina, is based on their superior tissue specificity over such conventional markers as creatine kinase [(CK); see Refs. (1)(2)]. Although CK is the most common serum marker for skeletal muscle injury, it is not ideal for several reasons, including lack of tissue specificity, inability to reveal damage to specific skeletal fiber types (fast or slow), and inappropriately low values when glutathione concentrations are decreased because of liver or multiple-organ failure (3). Skeletal troponin I (sTnI), with its two distinct isoforms [fast (fsTnI) and slow (ssTnI)], like cTnI and cTnT, may have a similar advantage over conventional markers for detecting skeletal-muscle injury.

In 1996, Rama et al. (4) described an experimental immunoenzymatic assay for sTnI using antibodies that cross-react with both sTnI and cTnI. The assumption of the investigators was that the concentrations of cTnI in patients with skeletal injury would be negligible. Others have since used this assay (5)(6)(7). For example, Onuoha et al. (7) found that serum sTnI reflects the severity and type of orthopedic and soft tissue injury. However, because this assay does not differentiate between the two isoforms of sTnI, which have a sequence homology of ~56%, information about selective damage to particular fiber types is unavailable. Posttranslational modifications to the analyte, such as degradation, are also undetected by this assay.

We applied our Western blot–direct serum . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
J. A. Simpson, R. Labugger, C. Collier, R. J. Brison, S. Iscoe, and J. E. Van Eyk
Fast and Slow Skeletal Troponin I in Serum from Patients with Various Skeletal Muscle Disorders: A Pilot Study
Clin. Chem., June 1, 2005; 51(6): 966 - 972.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. O'Connell, D. G. Stephenson, R. Blazev, and G. M. M. Stephenson
Troponin C isoform composition determines differences in Sr2+-activation characteristics between rat diaphragm fibers
Am J Physiol Cell Physiol, July 1, 2004; 287(1): C79 - C87.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. A. Simpson, J. Van Eyk, and S. Iscoe
Respiratory muscle injury, fatigue and serum skeletal troponin I in rat
J. Physiol., February 1, 2004; 554(3): 891 - 903.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.